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Screening – benefits or harms?
Screening asymptomatic patients is now an 
established part of medical practice. We routinely 
measure blood pressure, test urine, and carry out 
a chest X-ray pre-operatively. Screening is also 
offered to those who haven’t asked for medical 
intervention. Many medical aids advise women over 50 to have an 
annual mammogram and to have their bone mineral density (BMD) 
measured at various intervals. Some even reward these women in 
the form of ‘points’ in various schemes linked to medical cover. 
People are advised to have an annual health check that includes 
cholesterol measurement. Screening has become routine – but few 
stop and ask whether it is beneficial, and even fewer stop to look at 
potential harms.
I’m going to concentrate on two well-established screening 
programmes: screening mammography for breast cancer and 
screening for BMD. In the past 12 months alone, the British Medical 
Journal, the Lancet and the New England Journal of Medicine have 
published 24 articles or communications debating the value of 
breast cancer screening. Let’s ask the question that every screening 
intervention attempts to answer – does earlier treatment improve 
the prognosis? It has become an undisputed assumption that the 
earlier a cancer is diagnosed, the better the prognosis. But there is 
little evidence that this is in fact the case – and not just in breast 
cancer. In the CRC1 trial,[1] Haybittle et al. reported on a cohort 
of 2  800 women who were randomised to mastectomy with or 
without radiotherapy. The cohort was recruited at the same time as 
those in the old randomised trials of screening by mammography. 
The 10-year survival rate was about 55%. After around 8 years of 
follow-up, the curves for deaths other than breast cancer began to 
separate, favouring those women who avoided radiotherapy. Nearly 
20 years later, in 2008, Baum was co-author of a paper in the Lancet 
that compared adjuvent tamoxifen with adjuvent anastrozole for 
postmenopausal women with early breast cancer.[2] The 10-year 
survival in that cohort was 80%, with 5-year survival around 90%. 
Baum argues that as systemic therapy improves, the window for the 
impact of screening narrows and, as overdiagnosis rates increase, 
the importance of the relatively rare lethal toxicities of treatment 
increase. This brings me to the importance of overdiagnosis. Bleyer 
and Welch[3] estimate that about 30% of all breast cancers, or about 
50% of those detected by screening, are overdiagnosed each year 
in the USA. This rate of overdiagnosis is similar to that reported 
by the Nordic Cochrane Centre,[4] and translates to 70 000 women 
a year told that they have breast cancer who have pathology that 
will not become life threatening.[5] The harms of overdiagnosis 
are substantial. Anxiety associated with the ‘cancer’ label lasts 
a lifetime. Then there are the risks associated with surgery and 
anaesthetics. Women who go onto adjuvant therapy face a series 
of side-effects – alopecia, neutropenic sepsis, hot flushes, vaginal 
dryness and increased risk of fracture from endocrine treatment. 
Long-term consequences, which particularly concern Baum, are 
those associated with radiotherapy – cardiovascular and respiratory 
complications, reduced quality of life,[6] and treatment-induced 
secondary cancers. Baum, an outspoken critic of screening 
mammography for breast cancer, estimates from UK figures that 
over the 25 years of the National Health screening mammography 
programme, 3 - 4 deaths from breast cancer are avoided for every 
10 000 women screened. However, he points out that among these 
10 000 women, 120 to 140 cases will be overdiagnosed. Four-fifths 
of these women will receive radiotherapy and, as a consequence, 
be at increased risk of dying of ischaemic heart disease and lung 
cancer. He estimates that an additional 1 - 3 deaths might be 
expected from other causes for every breast cancer death avoided.[5]
Now to BMD. Just how well does a measurement of BMD predict 
fragility fractures? Norton Hadler, in his excellent book Rethinking 
Aging,[7] points out that we know that BMD is only one of many 
risk factors for fragility fractures. Age is one such risk factor – a 
55-year-old woman with a particular T score has a lower chance of 
a fragility fracture than a 70-year-old woman with the same T score, 
for example. That is true even for a low T score (-2.5 or less). The 
occurrence of one fragility fracture, whatever the T score, means 
an increased risk of another fracture. We have known for decades 
that older women (and men) have an increased risk of fragility 
fractures. The point of screening is to identify people ‘at risk’ and 
treat them early. But does screening by BMD for the risk of fragility 
fractures achieve this aim? A diagnosis of osteopenia – which 
will show up as a low T score – is known to be a poor predictor 
of future fragility fractures. This is because bone strength itself is 
not the only factor in a fragility fracture – neuromuscular health, 
for example, is at least as important, hence the greater risk of a 
fragility fracture in a 70-year-old than in a 55-year-old. To counter 
that – and to encourage continued screening – the World Health 
Organization Metabolic Bone Disease Group introduced the FRAX 
model. This model is based on multiple, easily measured risk factors 
such as age, gender, fracture history, use of oral steroids, presence of 
rheumatoid arthritis or other conditions associated with secondary 
osteoporosis, smoking status, family history, early menopause, low 
body mass index and excessive alcohol consumption. As a result of 
the FRAX model the International Osteoporosis Foundation and 
the National Osteoporosis Foundation in the USA recommend 
treating adults over 50 if their BMD score shows osteopenia and 
they are predicted to have a 10-year probability of hip fracture of 
3% or more and of any osteopenic fracture of 20% or more, based 
on FRAX. The problem is that the epidemiological data show no 
greater accuracy of fracture prediction using FRAX than simply 
BMD.[8] The other question that Hadler asks – one that I find 
particularly compelling – is, ‘Is osteopenia a disease?’. Are we not 
simply screening for a natural process of old age – or as Hadler 
puts it, ‘Screening by BMD for the risk of fragility fracture ... is 
basically an expensive way to ask a thin white or Asian woman her 
age’. This begs the question of intervention once osteopenia has 
been ‘diagnosed’, unfortunately beyond the scope of this editorial. 
Suffice it to say that the increasingly popular bisphosphonates do 
indeed treat the BMD score. Whether they actually prevent fragility 
fractures is more contentious, however.
Screening has become accepted medical practice over the 
past couple of decades – often with little or no epidemiological 
Could there be a patient with FABRY DISEASE in your practice?
Have you ever seen a child or adult with a wide range of unexplained 
signs and symptoms? There may also be a family history of 
unexplained pathologies and premature death. If this sounds familiar, 
could your patient have Fabry disease? 
Enzyme replacement therapy (ERT) for Fabry disease, which 
has recently become available in South Africa (agalsidase alfa; 
Replagal®; Shire HGT, Lexington, MA, USA; Litha Pharma–
Pharmaplan, Midrand, South Africa; registration number 43/31/0309).1 
It is therefore more important than ever for clinicians to follow up 
suspected cases of Fabry disease so that patients can receive the 
appropriate treatment in a timely manner. Because the condition is 
multi-systemic and can affect all major organ systems, physicians 
from many different specialities should be prepared to see patients 
with Fabry disease.2
What is Fabry disease and how will I recognize it?
Fabry disease is a slowly progressive, multi-systemic, life-limiting 
the ages of 3 and 10 years in males, and 6 and 15 years in females.3 
However, disease presentation, severity and rate of progression vary 
widely even among individuals in the same family, and disease onset 
may occur at any age.2,3 
In children, the most common early manifestations are a burning 
sensation in the extremities (acroparaesthesia), angiokeratoma, 
temperature intolerance, ocular signs (such as cornea verticillata), 
microalbuminuria, hearing loss and gastrointestinal disturbances, 
including nausea, vomiting, abdominal pain, diarrhoea and 
constipation.3,6 Older patients usually develop more extensive organ 
system involvement than younger individuals, characterized by 
proteinuria, impaired renal function, hypertrophic cardiomyopathy, 
arrhythmia and cerebrovascular involvement, such as stroke or 
transient ischaemic attacks. Facial dysmorphism may also be 
present.3 Importantly, disease expression is variable and not all 
patients with Fabry disease have all of the possible signs and 
symptoms.3 Affected individuals ultimately develop end-stage organ 
failure, leading to premature death in both men and women. Renal 
failure, cardiac disease and cerebrovascular disease are the most 
common causes of death.3
If you see a patient with some of the signs and symptoms described 
here, remember to keep in mind the possibility of Fabry disease.
How is Fabry disease treated?
ERT for Fabry disease consists of intravenous infusions of the 
α-galactosidase A enzyme. There are two forms of ERT for Fabry 
disease: agalsidase alfa (Replagal®; Shire HGT, Lexington, MA, USA; 
Litha Pharma–Pharmaplan, Midrand, South Africa; 0.2 mg/kg every 
other week), which was approved in South Africa in 2010, and agalsidase 
beta, which is not yet licensed in the country.1,3 Agalsidase alfa contains 
the human protein α-galactosidase A, produced in a human cell line by 
genetic engineering technology, and has been shown to be well tolerated 
cardiac and neurological manifestations of Fabry disease.1,9–13 
Symptomatic treatment using antiproteinurics, antihypertensives, 
analgesics and cardiac medications, for example, may also be 
appropriate. Regular, multidisciplinary follow-up is important for effective 
management of Fabry disease in both males and females.3
How should I proceed if I suspect Fabry disease?
In male patients, biochemical analysis of α-galactosidase A activity in 
3,14 Elevated levels of 
plasma or urinary globotriaosylceramide (Gb3) may also be 
3,14 In 
female patients, enzyme activity is often within the normal range and 
Gb3 levels are not always elevated. Genetic analysis is therefore 
required for formal diagnosis.3,14 A dried blood spot analysis kit is 
available to assist with diagnosis in both males and females. It is 
important to perform pedigree analysis after diagnosis of one family 
member so that relatives affected by this often debilitating condition 
If you would like more information on the topics discussed in this 
article, including how to obtain a dried blood spot analysis kit, please 
e-mail linda.bisset@lithahealthcare.co.za or call 083 417 6613.
Replagal® (agalsidase alfa) concentrate for solution for infusion. Scheduling 
status: Schedule 4. Registration number: 43/31/0309. Each 5 ml vial of 
concentrate contains 3.5 mg/3.5 ml of agalsidase alfa. Each 1 ml of solution 
contains 1 mg agalsidase alfa.
For full prescribing information refer to the package insert approved by the 
medicines regulatory authority. Further information is available on request to 
the holder of the registration: Pharmaplan (Pty) Ltd, Reg no.: 1996/017921/07. 
106 16th Road, Midrand 1685, telephone number 087 742 1860.  
A subsidiary of Litha Healthcare Group Limited. 
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How common is Fabry disease?
✦ Fabry disease is a rare condition, but may be more common 
than previously thought
✦ The incidence was previously estimated to be 1 in 117 000 
live births, but may in fact be as high as 1 in 3100 live male 
births4,5
What causes Fabry disease?
✦ It is the second most common of a group of inherited 
conditions known as lysosomal storage diseases, and is 
caused by mutations in the GLA gene that encodes the 
enzyme α-galactosidase A3
✦ 
accumulation of globotriaosylceramide (Gb3) in cells and 
tissues throughout the body3
✦ Inheritance is X-linked, but females may be as severely 
affected as males8
(a) (b)
Some of the most common early manifestations of Fabry disease: (a) cornea 
verticillata (courtesy of Dr Thomas Jansen, Bochum, Germany) and (b) 
angiokeratoma (reproduced from Sodi et al. 20067 with permission).
Advertorial supplied by Litha Pharma  
Tel: 087 742 1860  •  www.lithapharma.co.za
C
M
Y
CM
MY
CY
CMY
K
First Fabry adv Z.pdf   1   2013/04/19   9:11 AM
271  May 2013, Vol. 103, No. 5  SAMJ
evidence that it is fulfilling the 
requirements of a screening 
programme: that the screening 
modality shows what it is designed 
to show, the disease is important, 
and, having found the disease, we 
can do something about it. There 
is a growing movement[9] against 
‘overdiagnosis’ – a negative feature 
of modern medicine. A more 
rational and scientific approach 
to screening would be a good way 
to start addressing this problem.
Bridget Farham
Deputy Editor
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